GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 339.5 GBX 0.41% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GlaxoSmithKline PLC
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Accounts Payable
ÂŁ14.2B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
7%
AstraZeneca PLC
LSE:AZN
Accounts Payable
$20.5B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
7%
Verona Pharma PLC
NASDAQ:VRNA
Accounts Payable
$6.8m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Accounts Payable
$46m
CAGR 3-Years
19%
CAGR 5-Years
13%
CAGR 10-Years
-1%
Hikma Pharmaceuticals PLC
LSE:HIK
Accounts Payable
$541m
CAGR 3-Years
34%
CAGR 5-Years
17%
CAGR 10-Years
16%
Dechra Pharmaceuticals PLC
LSE:DPH
Accounts Payable
ÂŁ144.5m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
18%
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.6B GBX
Industry
Pharmaceuticals

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
2 340.58 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Accounts Payable?
Accounts Payable
14.2B GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Accounts Payable amounts to 14.2B GBP.

What is GlaxoSmithKline PLC's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
7%

Over the last year, the Accounts Payable growth was 2%.

Back to Top